How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity.

ABSTRACT: With growing indications for chimeric antigen receptor (CAR) T-cell therapy, toxicity profiles are evolving. There is an urgent and unmet need of approaches to optimally manage emerging adverse events that extend beyond the standard paradigm of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS). Although management guidelines exist for ICANS, there is little guidance on how to approach patients with neurologic comorbidities, and how to manage rare neurotoxicity presentations, such as CAR T-cell therapy-related cerebral edema, severe motor complications or late-onset neurotoxicity. In this study, we present 3 scenarios of patients treated with CAR T cells who develop unique types of neurotoxicity, and we describe an approach for the evaluation and m

SUBMITTER: Santomasso BD 

PROVIDER: S-EPMC10329188 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature